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RESEARCH ARTICLE

Open Access

Cyclic Vomiting Syndrome (CVS): is there a
difference based on onset of symptoms - pediatric
versus adult?
Nilay Kumar1, Qumseya Bashar2, Naveen Reddy3, Jyotirmoy Sengupta1, Ashwin Ananthakrishnan4,
Abigail Schroeder1, Walter J Hogan1 and Thangam Venkatesan1*

Abstract
Background: Cyclic Vomiting Syndrome (CVS) is a well-recognized functional gastrointestinal disorder in children
but its presentation is poorly understood in adults. Genetic differences in pediatric-onset (presentation before age
18) and adult-onset CVS have been reported recently but their clinical features and possible differences in response
to therapy have not been well studied.
Methods: This was a retrospective review of 101 CVS patients seen at the Medical College of Wisconsin between
2006 and 2008. Rome III criteria were utilized to make the diagnosis of CVS.
Results: Our study population comprised of 29(29%) pediatric-onset and 72 (71%) adult-onset CVS patients.
Pediatric-onset CVS patients were more likely to be female (86% vs. 57%, p = 0.005) and had a higher prevalence of
CVS plus (CVS + neurocognitive disorders) as compared to adult-onset CVS patients (14% vs. 3%, p = 0.05). There
was a longer delay in diagnosis (10 ± 7 years) in the pediatric-onset group when compared to (5 ± 7 years) adultonset CVS group (p = 0.001). Chronic opiate use was less frequent in the pediatric-onset group compared to adultonset patients (0% vs. 23%, p = 0.004). Aside from these differences, the two groups were similar with regards to
their clinical features and the time of onset of symptoms did not predict response to standard treatment. The
majority of patients (86%) responded to treatment with tricyclic antidepressants, anticonvulsants (topiramate),
coenzyme Q-10, and L-carnitine. Non-response to therapy was associated with coalescence of symptoms, chronic
opiate use and more severe disease as characterized by longer episodes, greater number of emergency department
visits in the year prior to presentation, presence of disability and non-compliance on univariate analysis. On
multivariate analysis, only compliance to therapy was associated with a response. (88% vs. 38%, Odds Ratio, OR 9.6;
95% Confidence Interval [CI], 1.18-77.05).
Conclusion: Despite reported genetic differences, the clinical features and response to standard therapy in
pediatric- and adult-onset CVS were mostly similar. Most patients (86%) responded to therapy and compliance was
the only factor associated with a response.
Keywords: Motility, Cyclic vomiting, Nausea, Abdominal pain
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Background
Cyclic vomiting syndrome (CVS) is a chronic gastrointestinal disorder that was initially described in children
but is now being recognized with increasing frequency
in adults [1-3]. Rome III criteria for CVS in adults
includes stereotypical episodes of vomiting regarding
onset (acute) and duration (less than 1 week); 3 or more
discrete episodes in the prior year and absence of nausea
and vomiting between the episodes [4]. Adult CVS can
range from mild disease with infrequent episodes to severe life-disabling disease requiring multiple emergency
department (ED) visits and frequent hospitalizations
[1,5,6]. Since CVS is often unrecognized, these patients
often undergo a battery of unnecessary diagnostic and
therapeutic procedures without any clinical benefit [1,7].
Many patients, if not treated appropriately, develop coalescence of symptoms with interepisodic nausea and
loss of the periodicity of episodes. Several CVS patients
also undergo unnecessary surgical procedures such as
cholecystectomy for symptoms caused by CVS [7].
CVS may be categorized as pediatric- and adult-onset
CVS based on the age of onset of symptoms. Pediatriconset CVS patients develop symptoms prior to the age
of 18 while adult-onset CVS patients develop symptoms ≥ 18 years [1,8]. Genetic differences have been
identified in these two groups with mitochondrial DNA
(mtDNA) mutations, 16519 T and 3010A being associated with pediatric-onset CVS [2,9-11].
Strong maternal inheritance of multiple disease manifestations and abnormal urine organic acids has been
demonstrated in children with CVS, suggesting the presence of predisposing mtDNA sequence polymorphisms
[12,13]. It has also been reported that pediatric-onset
CVS patients have a higher proportion of maternal inheritance of functional symptomatology as ascertained
by quantitative pedigree analysis [14].There are presently
no data that have elucidate the clinical differences and
response to treatment pertaining to these groups . Based
on our experience with a large cohort of CVS patients
seen at the adult CVS clinic in Milwaukee, we hypothesized that despite these genetic differences, both groups
of patients had similar clinical characteristics and response to standard medications used in the treatment of
CVS. For treatment of these patients we also utilized the
standard medical regimen shown to be effective in existing literature [15].
Aims
The primary aims of our study were 1) To define the
demographics and clinical characteristics and assess response to therapy in pediatric-onset and adult-onset
CVS patients. 2) To identify predictors of response to
treatment in both groups of patients.
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Results
Study population

Of 101 patients, there were 66 (65%) females. There
were 79 (79%) whites, 17(17%) blacks, 3 (3%) of hispanic
origin and 1 (1%) of other origin. Six patients met the
diagnostic criteria for CVS plus whereas 10 patients met
criteria for catamenial CVS (episodes triggered by menstrual periods) [1]. CVS plus is defined as CVS in association with neurocognitive disorders [16]. The mean age
at presentation was 27 ± 12.3 years. The median duration of an episode was 3 days (range 1-18 days) with 81
(81%) patients reporting a prodromal phase. At the initial clinic visit, 39 (39%) patients had coalescence of
symptoms with daily or near-daily symptoms but had
typical episodes at the outset. Patients with coalescent
CVS had a longer delay in diagnosis as compared to typical CVS patients (91 ± 86 vs. 75 ± 85 months) though
this was not statistically significant. Of all patients, 63
(62%) had abdominal pain as a prominent symptom during episodes along with nausea and vomiting. The location of the abdominal pain was variable with 40 patients
(63%) having generalized abdominal pain, 14 patients
(22%) reporting upper abdominal pain and 9 patients
(15%) with pain in the lower abdomen. Almost all
patients (90%) had nausea as a part of their symptom
complex and 76 patients (76%) stated that the onset of
episodes was in the morning. Data on hot and cold
showers was available in 73 patients; 38 (52%) patients
had symptom relief with hot showers and 1 patient had
relief with a cold shower. Hot showers were reported in
25/35 (71%) CVS patients using marijuana when compared to non users 19/56 (34%, p = 0.01).
Triggers for CVS episodes were reported in 87(87%)
of patients with the most common triggers being negative stress (unpleasant or sad events) in 67(67%) and
positive stress (happy or exciting events) in 59(59%).
The recovery phase was very variable and ranged from
10 minutes – 7 days. Many patients had concomitant
co-morbid conditions such as anxiety (47%), depression
(49%) and dysautonomia (64%). Gastric emptying studies were available for review in 40 patients; 10 patients
(25%) had gastroparesis whereas 4 patients (10%) had
rapid gastric emptying and 26 (65%) had normal
emptying.
Thirty of seventy (43%) patients had a personal history
of migraine and 41/64(64%) had a family history of migraine. Most of the patients in our cohort had undergone numerous diagnostic and therapeutic procedures;
28/92 (30%) had undergone a cholecystectomy for symptoms of CVS without any therapeutic benefit. Eighteen
of 75 patients (24%) reported some form of disability
from CVS. Sixteen (24%) of 66 patients had a delay in
higher education and 20 of 70 patients (29%) reported
job loss related to CVS episodes.

Kumar et al. BMC Gastroenterology 2012, 12:52
http://www.biomedcentral.com/1471-230X/12/52

Page 3 of 7

Table 1 Demographic and disease characteristics of
patients with CVS based on disease onset
Variables

Pediatric Onset
(n-29),

Adult Onset
(n-72)

p-value

Mean age at onset
of symptoms(years)

13.4±12.5

32.3±12.3

0.0001

Female sex

25 (86%)

41 (57%)

0.005

White

25 (86%)

54 (75%)

0.29

Black

3 (10%)

14 (20%)

0.38

Hispanic

1 (4%)

2 (3%)

1

Other

0

1 (1%)

4 (14%)

2 (3%)

Race (%)

Type of CVS
CVS plus (%)

0.05

Catamenial CVS

5 (17%)

5 (7%)

0.15

Sato’s CVS

2 (7%)

4 (6%)

1

Delay in diagnosis
(months)

124.75±85.86

63.53±85.23

0.001

Coalescence

14 (48%)

25 (36%)

0.25

Associated Symptoms Available n = 27 Available n = 67
Abdominal Pain

16 (59%)

Co-morbid disorders

Available n = 28 Available n = 68

47 (70%)

0.34

IBS

9 (32%)

18 (27%)

0.62

Anxiety

13 (46%)

32 (47%)

0.19

Depression

9 (32%)

33 (49%)

0.18

Bipolar Disorder

1 (4%)

1 (2%)

0.5

Migraine

16 (55%)

30 (43%)

0.28

Cholecystectomy

9 (32%)

19 (30%)

0.81

Family History (%)

Available n = 25 Available n = 64

Family history of
migraine

16 (64%)

Drug use %

Available n = 27 Available n = 65

Marijuana

8 (30%)

27 (42%)

0.35

Alcohol

7 (26%)

10 (15%)

0.25

Tobacco

3 (12%)

30 (46%)

0.001

Narcotics

0

15 (23%)

0.004

Response to therapy

19/20 (95%)

47/56 (84%)

0.27

41 (64%)

1

symptoms, or personal/family history of migraine. Coalescence of symptoms was noted in both pediatric- and
adult-onset CVS. There were no significant differences
in response to treatment in both groups of patients
(p = 0.27).
Pediatric-onset CVS patients differed from adult-onset
CVS in having a higher prevalence of CVS-plus. (14% vs.
3%, p = 0.05). There was a marked delay in diagnosis in
both groups but those with pediatric-onset CVS has a
much longer mean delay in diagnosis in comparison to
adult- onset CVS (10 ± 7 vs. 5 ± 7 years, p = 0.001).
Adult-onset CVS patients had a significantly higher incidence of tobacco and narcotic use of 46% and 23% when
compared to 12% and 0% in the pediatric-onset group
(p = 0.001 and 0.004 respectively).
Treatment profile of patients with CVS and variables
associated with response to treatment

Most patients 70/92 (76%) were on tricyclic antidepressants (TCA) such as amitriptyline or nortriptyline, 18 /92
patients (20%) on topiramate and 27/92 (30%) on coenzyme Q-10, L-carnitine or riboflavin. Of the 77 patients
with adequate data on response to triptans as abortive
therapy, 64 (83%) patients were able to abort episodes.
Of the 70 patients on tricyclic antidepressants, 18
patients (26%) had to stop the medication due to drug intolerance; the most common adverse effects included
bad dreams, behavioral changes and increased somnolence. The mean dose of TCA used in patients who tolerated therapy was 83.3 ± 36.6 mg. Adequate follow up
data was available in 76/101(75%) patients (75%) who
were initiated on medical therapy and mean duration of
follow-up was 11.2 ± 6.2 months. Response to treatment
in these patients is depicted in figure 1. The majority of
patients responded to treatment with 44 (58%) patients
having a complete response, 21(28%) a partial response
and 11(14%) patients with no response to therapy. There
were no significant differences in the type of medications
or dosages used in complete, partial and non-responders.
(Figure 2)

Pediatric- vs. adult-onset CVS

In our cohort of 101 adults with CVS, twenty nine
patients (29 %) had pediatric-onset CVS as compared to
72 (71 %) with adult-onset CVS. The demographics,
clinical characteristics, associated co-morbid conditions
and response to treatment are depicted in table 1.
Patients were predominantly white in both groups but
more patients were female in those with pediatric-onset
CVS 25 (86 %) than adult-onset CVS 41(57 %),
(p = 0.005). Both subgroups had similar disease characteristics with no significant differences noted in trigger
factors, co-morbid conditions, rate of surgery for CVS

Figure 1 Response profile of CVS patients.
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Figure 2 Medications used in complete, partial and non-responders did not reveal any significant differences.

The demographics and clinical characteristics of responders (both complete and partial) and non-responders
are depicted in table 2. On univariate analysis, nonresponders were more likely to have a pattern of coalescence (82% vs. 34% p = 0.005). They also had had longer
Table 2 Univariate analysis of responders and
nonresponders to treatment
Variables

Responders
Non-Responders p-value
[Partial n-21;
(n-11)
Complete n-44]

Pediatric onset

31

18

0.49

Gender

63

64

1

White %

82

82

1

Black %

14

18

0.66

Coalescence %

34

82

0.005

Narcotics %

13

45

0.02

Compliance %

88

38

0.004

Loss of job %

31

57

0.21

Females %
Race

Disability %

20

57

0.05

Surgery for CVS %

29

30

1

No. of episodes/yr

31.3±50

46.6±52.8

0.4

6.5±3.5

0.008

Duration of episodes (days) 3.5±3.5
Warning phase (Minutes)

159.2±365

47.1±378.1

0.45

Recovery Phase (days)

1.7±1.9

2.2±1.9

0.43

No. of emesis/hr

12.2±17.1

19.1±17.4

0.31

ED visits last year

3.4±9

15.8±9.2

0.0002

Number of hospitalizations 11.5±31.8

31±32

0.08

Average duration
of hospitalizations

3.3±8.8

0.57

5.1±8.8

episodes lasting 6.5 days vs. 3.5 days and greater numbers
of ED visits (15 vs. 3) in the year prior to evaluation compared to responders. The incidence of chronic opiate use
was significantly higher amongst non-responders than
responders (46% vs. 13%, p = 0.02). A significantly higher
rate of disability amongst non-responders was also noted
(57 % vs. 20 %, p = 0.05). Non-responders were less likely
to be compliant to treatment (38 % vs. 88 %, p = 0.004).
On multivariate analysis only compliance was found to
be statistically significant in predicting response to treatment (p = 0.03, OR 9.6, 95 % CI 1.18-77.05).

Discussion
The salient findings of our study are that both adultand pediatric-onset CVS patients have a similar demographic profile and disease characteristics except that
pediatric-onset patients were more likely to be female
and had a higher prevalence of CVS-plus with concomitant neurological disorders. This finding may be
explained by the genetic differences that have been elucidated in previous studies [2,10,11]. The pediatric-onset
group also had a lower incidence of tobacco and opiate
use and a significantly longer delay in diagnosis of CVS.
This longer delay in diagnosis is an unexpected finding
given that CVS is fairly well-recognized condition in
children. It should be noted that though our center
attracts both children and adults with CVS, the majority
of the patients with pediatric-onset CVS were not transitioned from the Children's Hospital of Wisconsin, which
is also a tertiary center for pediatric CVS. Dysautonomia
was diagnosed in 64 % of our CVS patients which we recently reported to be a significant problem in this population [17]. Similar to reported literature, CVS patients
in both groups had a strong personal or family history
of migraine [18,19]. Co-morbid conditions including
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anxiety, depression and irritable bowel syndrome were
seen in both groups and it is unclear if this is related
to the lack of receiving a credible diagnosis and the inordinate delay in treatment that these patients experience. In addition, 30 % of patients underwent invasive
surgery for CVS symptoms without any benefit. Long
delays in diagnosis along with such unnecessary and
unhelpful interventions are unacceptable both from a
patient standpoint and from an economic perspective.
The majority of our patients (86 %) had either a
complete or partial response to prophylactic medications with TCA’s, topiramate and mitochondrial therapy
such as carnitine, coenzyme Q-10 and ribofavin. The
dose of carnitine used was 1 gram twice daily, co-enzyme
Q-10 was 200 mg twice daily and riboflavin 100 mg once
daily. On univariate analysis, non-response to therapy
was associated with coalescence of symptoms, chronic
opiate use and more severe disease as characterized by
longer episodes, greater number of ED visits in the year
prior to presentation, presence of disability and noncompliance. Compliance was the only significant variable
on multivariate analysis that predicted response to therapy. Patients were deemed noncompliant if they continued to use marijuana and it is the practice of the author
to advise complete abstinence from marijuana in all
patients. We did not routinely check for cessation of
marijuana in our patients with toxicology screens. There
was no difference in response to therapy between
pediatric-onset and adult-onset CVS patients despite recent reports of genetic differences. This may imply that
there are other factors involved in the pathogenesis of
this disorder aside from mitochondrial abnormalities
in adults.
The few patients who were administered TCA’s prior
to being seen at our clinic were on a low daily dose of
25 mg that is employed in other functional gastrointestinal disorders. Dose escalation to 1 mg/kg as used in
children produced the desired therapeutic effect. However, there was a high incidence of side effects associated
with TCA therapy resulting in discontinuation in 26% of
patients which limited its use [20].
Marijuana use was seen in more than a third of
patients with CVS and patients frequently reported
using this for alleviation of nausea and as an appetite
stimulant. There did not appear to be any clear causeand-effect or temporal relationship between the use of
marijuana and onset of symptoms based on clinical history and these patients were not thought to have symptoms caused by the use of marijuana. Marijuana use has
been thought to result in cannabinoid hyperemesis [2123]. Though the patients reported in the literature have
not had adequate follow up; this entity as a separate disorder is subject to controversy. This raises questions
about whether chronic marijuana use down regulates
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CB1 receptors and paradoxically causes more nausea
and vomiting which will need to be evaluated in the future studies.
We acknowledge that there are several limitations to
this study as this was a retrospective analysis though the
data was also obtained prospectively with a standardized
questionnaire used in clinic. The response to medications has been arbitrary in CVS thus far and there has
been no consensus or accepted definitions in adult
patients for measures of response to treatment in CVS.
ED utilization has been recently studied in CVS patients;
we used overall improvement of symptom frequency and
severity to assess response to treatment [24]. We were
unable to report on exact numbers of ED visits prior to
and after treatment as many patients visited other ED’s
for CVS episodes. In addition while other authors have
measured ED visits and hospitalizations as outcomes of
therapy, some patients with CVS have home intravenous
fluid therapy or are seen in infusion clinics as in our
practice to help control their symptoms and avoid long
waits in the ED and prevent hospitalizations. Our study
is one of the largest studies characterizing adult-onset
and pediatric-onset CVS patients. This study should
pave the way for future prospective evaluation of treatment in patients with CVS and standardized measures
of disease outcomes.

Conclusion
In conclusion, adult-onset CVS patients have similar
symptoms to those with pediatric- onset CVS and have
similar rates of response to therapy. CVS patients appear
to respond favorably to higher doses of TCA’s of 1 mg/kg
in comparison to the lower doses that are used in other
functional gastrointestinal disorders. CVS is associated
with an enormous psychosocial and economic burden
and patients must be diagnosed early and treated with
appropriate medications. Combination of medical and
behavioral therapy based on a bio-psycho-social model is
key to successfully treating patients.
Methods
Study population

A retrospective review of 101 adults with CVS seen at
the Medical College of Wisconsin between September
2006 and October 2008 was performed. The adult CVS
clinic at the Medical College of Wisconsin (MCW)
serves as a tertiary referral center for patients with CVS.
Patients were identified based on the Rome III criteria
for CVS and comprised of patients from 15 states in the
USA and Canada. Data was collected at the time of initial patient visit and subsequent follow up visits. All
patients had stereotypical episodes at onset but some
patients developed coalescence of symptoms later when
they developed significant interepisodic nausea and
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dyspepsia and lost the typical periodicity seen during the
initial phase of their illness. Patients with coalescence of
symptoms were included only if they had episodic symptoms at the outset.
Data collection

Demographic characteristics including age, gender, race,
geographic location, personal and family history of all
patients were collected at the time of initial evaluation
with a standard questionnaire that was completed by
patients prior to their appointment. This was then
reviewed at the time of the initial clinic visit and information was confirmed. Data was collected on disease
characteristics such as duration and severity of disease,
age of onset, delay in diagnosis, specific triggers, associated co-morbid conditions, history of marijuana use
and number of emergency department (ED) visits and
hospitalizations. Medications used as prophylactic therapy in CVS including tricyclic antidepressants such as
amitriptyline and nortriptyline, anti-epileptics such as
topiramate and mitochondrial supplements such as coenzyme Q-10, L-carnitine, and riboflavin were recorded.
Adverse effects of medications, response to treatment,
disability and job loss due to CVS were ascertained. Data
was collected on a Microsoft Excel spreadsheet; most of
the variables were in a categorical format with some data
such as number of ED visits and hospitalizations
recorded as continuous variables. Data was collected as
per the historical recollection of the patient with supplementation from previous medical records. The patients
were divided based on time of onset of symptoms
(pediatric-onset and adult-onset) and response to therapy [1]. This study was approved by Institutional Review
Board at the Medical College of Wisconsin.
All patients seen in our clinic were asked standard
questions about the frequency, duration and severity of
episodes. Complete response to therapy was defined as
≥ 80 % amelioration in symptom duration, frequency
and severity and partial response was at least a 50-80 %
reduction. Non-responders had either no change in their
disease status or < 50 % reduction in symptom duration,
frequency and severity. Patients were deemed compliant
if they reported taking their prescribed medications and
either discontinued or reduced their marijuana intake
significantly. Cessation of marijuana use was not verified
routinely with a drug screen.
Data analysis

The data was analyzed using the Stata (StataCorp, College Station, TX). Categorical variables were summarized
using proportions while continuous variables were summarized using means and standard deviation. The Fisher’s exact test or the chi-square test was used to perform
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between-group comparisons of categorical variables. The
t-test was used for comparing continuous variables.
Univariate logistic regression was performed to identify
variables associated with the dichotomous outcomes of
interest, namely pediatric onset disease and response
(complete / partial response vs. non-response) to therapy.
Linear regression was used for continuous outcomes including number of hospitalizations, ED visits, duration of
episodes and number of episodes. Variables that were significant in these regression models at p < 0.1 were
selected for inclusion in the final multivariate model
where p < 0.05 was indicative of independent statistical
significance.
Abbreviations
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CI: Confidence Interval.
Competing interests
The authors declare that they have no competing interests.
Acknowledgement
We would like to acknowledge the Cyclic Vomiting Syndrome Association
for contributing towards publications costs.
Author details
1
Department of Gastroenterology and Hepatology, Medical College of
Wisconsin, 4th Floor, Froedtert East Building, 9200 W Wisconsin Avenue,
Milwaukee, WI 53226, USA. 2Mayo Clinic Florida, Florida, USA. 3Wayne State
University, Detroit, USA. 4Massachusetts General Hospital, Massachusetts, USA.
Author contribution
NK Acquisition of the data Analysis and interpretation of the data Drafting of
the manuscript Revisions and corrections. QB Collection of data Organization
of the data Review of charts and follow-up. NR Acquisition of the data
Review of literature Drafting of the tables/figures. JS Administrative,
technical, or material support Organization of the data Review of literature.
AA Statistical Analysis Critical review of manuscript. AS Acquisition of data
Patient recruitment and follow-up. WJH Study concept and design Critical
review of the manuscript. TV Study concept and design Drafting of
manuscript Critical review of the manuscript Study overview.
Received: 17 December 2011 Accepted: 28 May 2012
Published: 28 May 2012
References
1. Abell TL, Adams KA, et al: Cyclic vomiting syndrome in adults.
Neurogastroenterol Motil 2008, 20(4):269–284.
2. Boles RG, Zaki EA, et al: Are pediatric and adult-onset cyclic vomiting
syndrome (CVS) biologically different conditions? Relationship of adultonset CVS with the migraine and pediatric CVS-associated common
mtDNA polymorphisms 16519T and 3010A. Neurogastroenterol Motil 2009,
21(9):936–e72.
3. Fleisher DR, Matar M: The cyclic vomiting syndrome: a report of 71 cases
and literature review. J Pediatr Gastroenterol Nutr 1993, 17(4):361–369.
4. Tack J, Talley NJ, et al: Functional gastroduodenal disorders.
Gastroenterology 2006, 130(5):1466–1479.
5. Pareek N, Fleisher DR, et al: Cyclic vomiting syndrome: what a
gastroenterologist needs to know. Am J Gastroenterol 2007, 102(12):
2832–2840.
6. Prakash C, Clouse RE: Cyclic vomiting syndrome in adults: clinical features
and response to tricyclic antidepressants. Am J Gastroenterol 1999, 94
(10):2855–2860.
7. Fleisher DR, Gornowicz B, et al: Cyclic Vomiting Syndrome in 41 adults:
the illness, the patients, and problems of management. BMC Med 2005,
3:20.

Kumar et al. BMC Gastroenterology 2012, 12:52
http://www.biomedcentral.com/1471-230X/12/52

8.
9.

10.

11.

12.

13.
14.

15.

16.
17.

18.
19.
20.

21.

22.
23.
24.

Page 7 of 7

Prakash C, Staiano A, et al: Similarities in cyclic vomiting syndrome across
age groups. Am J Gastroenterol 2001, 96(3):684–688.
Boles RG, Lovett-Barr MR, et al: Treatment of cyclic vomiting syndrome
with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol
2010, 28:10–10.
Camilleri M, Carlson P, et al: Mitochondrial DNA and gastrointestinal
motor and sensory functions in health and functional gastrointestinal
disorders. Am J Physiol Gastrointest Liver Physiol 2009, 296(3):G510–G516.
Zaki EA, Freilinger T, et al: Two common mitochondrial DNA
polymorphisms are highly associated with migraine headache and cyclic
vomiting syndrome. Cephalalgia 2009, 29(7):719–728.
Li BU, Lefevre F, et al: North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition consensus statement on
the diagnosis and management of cyclic vomiting syndrome. J Pediatr
Gastroenterol Nutr 2008, 47(3):379–393.
Boles RG, Adams K, et al: Maternal inheritance in cyclic vomiting
syndrome. Am J Med Genet A 2005, 133A(1):71–77.
Venkatesan T, Wagler S, et al: M2013 Cyclic Vomiting Syndrome:
Quantitative Pedigree Analysis for Maternal Inheritance Patterns in
Adults and Children. Gastroenterology 2010, 138(5):S-458. Supplement 1.
Andersen JM, Sugerman KS, et al: Effective prophylactic therapy for cyclic
vomiting syndrome in children using amitriptyline or cyproheptadine.
Pediatrics 1997, 100(6):977–981.
Boles RG, Powers AL, et al: Cyclic vomiting syndrome plus. J Child Neurol
2006, 21(3):182–188.
Venkatesan T, Prieto T, et al: Autonomic nerve function in adults with
cyclic vomiting syndrome: a prospective study. Neurogastroenterol Motil
2010, 22(12):1303–1307.
Fleisher DR: Cyclic vomiting syndrome and migraine. J Pediatr 1999, 134
(5):533–535.
Li BU, Murray RD, et al: Is cyclic vomiting syndrome related to migraine?
J Pediatr 1999, 134(5):567–572.
Hejazi RA, Reddymasu SC, et al: Efficacy of tricyclic antidepressant
therapy in adults with cyclic vomiting syndrome: a two-year follow-up
study. J Clin Gastroenterol 2010, 44(1):18–21.
Allen JH, de Moore GM, et al: Cannabinoid hyperemesis: cyclical
hyperemesis in association with chronic cannabis abuse. Gut 2004, 53
(11):1566–1570.
Ochoa-Mangado E, Jimenez Gimenez M, et al: Cyclical hyperemesis
secondary to cannabis abuse. Gastroenterol Hepatol 2009, 32(6):406–409.
Sannarangappa V, Tan C: Cannabinoid hyperemesis. Intern Med J 2009, 39
(11):777–778.
Venkatesan T, Tarbell S, et al: A survey of emergency department use in
patients with cyclic vomiting syndrome. BMC Emerg Med 2010, 10:4.

doi:10.1186/1471-230X-12-52
Cite this article as: Kumar et al.: Cyclic Vomiting Syndrome (CVS): is there
a difference based on onset of symptoms - pediatric versus adult?. BMC
Gastroenterology 2012 12:52.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

